About the Company:
Divi’s lab is a global manufacturing pharmaceutical unit who is severing more than 28 years in the Indian market. The company was established in 1990, headquartered in Hyderabad, India. Divi’s Lab is recognized as a ‘Reliable Supplier of generic APIs (Active pharmaceuticals ingredients)’, Intermediates and Registered starting materials offering high-quality products with the highest level of compliance.
QoQ & YoY Performance:
India’s one of the leading Pharma Company has declared the results for the third quarter of the fiscal year ending March 2020.
- Total Revenue: The consolidated Net Revenue for the quarter increased by 2.67% to Rs. 139626 lakhs, from Rs. 135996 lakhs in the same period last year.
- Net Profit: The Company has posted consolidated a net profit reduced by 7.78% of Rs 35909 Lakhs in Q3FY20 over Rs 38939 Lakhs in the same period last year. While Profit Margins also reduced to 25.72% for the quarter ended 31st Dec’19. Forex loss for the current quarter amounted to Rs. 6 crores as against a gain of Rs. 26 crores during the corresponding quarter of the last year.
- EBITDA Margins: Margins for the quarter reduced to 38.36% from 41.71% on YoY basis.
- INTERIM Dividend: Company declared an Interim Dividend of Rs. 16/- per equity share of Rs. 2/- each for the financial year 2019-20.
As per Lokesh Sethia, SEBI Registered Research Analyst, the stock is trading at Rs.2136.15 per share, due to the average result; the target will be Rs. 2450.00 per share for Long-Term view.
This is for the sole purpose to provide client(s) information of EQUITY GLOBAL RESEARCH (EG) and not to interpret as investment advice. It is also not to consider as an offer or solicitation for the purchase and sale of any financial instrument. Any action taken based on given information contained herein is your responsibility alone. EQUITY GLOBAL RESEARCH and its subsidiaries/employees/associates will not be liable in any manner for the consequences of such action taken by you. The due diligence we have exercised after checking the correctness and authenticity of the information contained in this recommendation. In case of any inadvertent error in the given information to make this recommendation or action taken based on information the EQUITY GLOBAL RESEARCH or any of its subsidiary or associate or employee shall not be liable in any way responsible for any loss or damage. The recommendations provided here based on either Technical Analysis, Fundamental Analysis or both. EQUITY GLOBAL RESEARCH has issued this document on information obtained from sources it believes to be reliable but not independently verified; Also, the EQUITY GLOBAL RESEARCH makes no promises, guarantee, or accepts no responsibility as to its accuracy or completeness. The opinions contained within the report based on publicly available information at the time of publication and subject to change without any intimation. Any piece of information and disclosure provided herein is in summary form and has been prepared for informational purposes. The recommendations are only valid for the day of the issued report however, trading trends, volumes might vary substantially on a daily basis, and recommendations may change accordingly. The information provided herein is entirely confidential. Any misuse, distribution, modification, copying, or forwarding by any person strictly prohibited. The information provided herein does not constitute a solicitation or offer to buy or sell any security or other financial instruments. The current performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investment will achieve any targeted rates of return, and there is no guarantee against the loss of your entire investment.